JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB98234

Recombinant Human ACADVL/VLCAD protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human ACADVL/VLCAD protein is a Human Full Length protein, in the 41 to 655 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE.

View Alternative Names

VLCAD, ACADVL

1 Images
SDS-PAGE - Recombinant Human ACADVL/VLCAD protein (AB98234)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human ACADVL/VLCAD protein (AB98234)

15% SDS-PAGE analysis of 3μg ab98234

Key facts

Purity

>90% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

P49748

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.316% Tris HCl, 0.0292% EDTA, 0.0154% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Previously labelled as ACADVL.
style
left-column

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMAGGAAQLALDKSDSHPSDALTRKKPAKAESKSFAVGMFKGQLTTDQVFPYPSVLNEEQTQFLKELVEPVSRFFEEVNDPAKNDALEMVEETTWQGLKELGAFGLQVPSELGGVGLCNTQYARLVEIVGMHDLGVGITLGAHQSIGFKGILLFGTKAQKEKYLPKLASGETVAAFCLTEPSSGSDAASIRTSAVPSPCGKYYTLNGSKLWISNGGLADIFTVFAKTPVTDPATGAVKEKITAFVVERGFGGITHGPPEKKMGIKASNTAEVFFDGVRVPSENVLGEVGSGFKVAMHILNNGRFGMAAALAGTMRGIIAKAVDHATNRTQFGEKIHNFGLIQEKLARMVMLQYVTESMAYMVSANMDQGATDFQIEAAISKIFGSEAAWKVTDECIQIMGGMGFMKEPGVERVLRDLRIFRIFEGTNDILRLFVALQGCMDKGKELSGLGSALKNPFGNAGLLLGEAGKQLRRRAGLGSGLSLSGLVHPELSRSGELAVRALEQFATVVEAKLIKHKKGIVNEQFLLQRLADGAIDLYAMVVVLSRASRSLSEGHPTAQHEKMLCDTWCIEAAARIREGMAALQSDPWQQELYRNFKSISKALVERGGVVTSNPLGF","proteinLength":"Full Length","predictedMolecularWeight":"68.5 kDa","actualMolecularWeight":null,"aminoAcidEnd":655,"aminoAcidStart":41,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P49748","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ACADVL also known as VLCAD (Very Long-Chain Acyl-CoA Dehydrogenase) is an enzyme that plays an important role in the breakdown of long-chain fatty acids within the mitochondria. It has a molecular mass of approximately 70 kDa. VLCAD is expressed in various tissues with high levels found in the heart skeletal muscle and liver. These tissues are heavily reliant on fatty acid oxidation for energy production especially when glucose availability is low.
Biological function summary

ACADVL functions within the mitochondrial matrix where it catalyzes the initial step of beta-oxidation by desaturating long-chain acyl-CoA molecules. This enzyme is a part of a larger complex that includes other mitochondrial dehydrogenases contributing to the degradation of fatty acids into acetyl-CoA units. The process is essential for energy production especially under fasting conditions or high-energy demand scenarios such as muscle contraction and cardiac function.

Pathways

VLCAD plays an essential role in the fatty acid beta-oxidation pathway. It works alongside other enzymes such as ACADM (Medium-Chain Acyl-CoA Dehydrogenase) to facilitate the sequential shortening of fatty acids which integrates into the Krebs cycle for further energy extraction. This pathway maximizes energy yield from fatty acids significantly influencing cellular metabolism and energy homeostasis.

VLCAD deficiencies lead to severe metabolic conditions such as VLCAD deficiency. This disorder results in the impaired breakdown of long-chain fatty acids causing energy deficiency and the accumulation of toxic substances. Symptoms range from muscle weakness to serious cardiac complications. VLCAD deficiency's impact is often assessed in relation to proteins like ACSL1 and CPT2 which are involved in the fatty acid metabolism pathway and are central to effective energy processing in cells.
style
left-column

Specifications

Form

Liquid

Additional notes

ab98234 was purified using conventional chromatography techniques.

style
left-column

General info

Function

Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed : 18227065, PubMed : 7668252, PubMed : 9461620, PubMed : 9599005, PubMed : 9839948). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed : 18227065, PubMed : 7668252, PubMed : 9461620, PubMed : 9839948). Among the different mitochondrial acyl-CoA dehydrogenases, very long-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (PubMed : 21237683, PubMed : 9839948).

Sequence similarities

Belongs to the acyl-CoA dehydrogenase family.

Post-translational modifications

S-nitrosylation at Cys-237 in liver improves catalytic efficiency.

Subcellular localisation

Mitochondrion inner membrane

style
left-column

Product protocols

style
left-column

Target data

Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed : 18227065, PubMed : 7668252, PubMed : 9461620, PubMed : 9599005, PubMed : 9839948). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed : 18227065, PubMed : 7668252, PubMed : 9461620, PubMed : 9839948). Among the different mitochondrial acyl-CoA dehydrogenases, very long-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (PubMed : 21237683, PubMed : 9839948).
See full target information ACADVL
style
left-column
style
left-column
style
right-column

Complementary Products

Cell Lines & Lysates

AB150035

HeLa whole cell lysate

Western blot - HeLa whole cell lysate (AB150035)

  • 0
  • 0
Cell Lines & Lysates

AB166833

Hep G2 whole cell lysate

  • 0
  • 0
Primary Antibodies

AB230667

Anti-HADHB antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HADHB antibody (AB230667)

  • 0
  • 0
Assay Kits

AB227894

Human Niemann Pick C2 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human Niemann Pick C2 ELISA Kit (AB227894)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com